Human Normal Immunoglobulin for Intravenous use IP 5%

Advanced Immune Support and Immunomodulatory Therapy

Human Normal Immunoglobulin for Intravenous Use IP 5% (often referred to as IVIG) is a sterile, highly purified solution of human antibodies concentrated at a 5% strength. It is prepared from large pools of healthy donor plasma and conforms strictly to Indian Pharmacopoeia (IP) standards. This critical, life-saving therapy provides immediate passive immunity by delivering a broad spectrum of neutralising IgG antibodies to patients with compromised immune systems or complex autoimmune disorders.

How It Works

Immunoglobulins are vital proteins that your immune system uses to identify and destroy foreign invaders like bacteria and viruses. When administered intravenously, this 5% solution quickly raises abnormally low antibody levels back into a healthy range, defending the body against severe infections.

Additionally, in autoimmune conditions, these infused antibodies help modulate and calm a misdirected immune system, stopping it from attacking the body’s own healthy tissues.

Key Applications

• Primary Immunodeficiency Diseases (PIDD): Provides essential replacement therapy for individuals born with a lacking or absent immune defense.

• Secondary Immunodeficiencies: Supports patients experiencing severe antibody failure due to conditions like Chronic Lymphocytic Leukemia (CLL) or post-bone marrow transplants.

• Autoimmune & Inflammatory Disorders: Used as a first-line treatment to regulate immune responses in conditions like Immune Thrombocytopenic Purpura (ITP), Kawasaki disease, and Guillain-Barré syndrome.

Clinical Specifications & Safety

• Administration: Must be administered strictly via slow intravenous infusion under the direct supervision of qualified healthcare professionals in a hospital or clinical setting.

• Viral Safety: Produced using multi-step, state-of-the-art purification techniques—including pasteurisation and nanofiltration—to guarantee a superior viral inactivation and safety profile.

Important Safety Notice: IVIG infusions must be monitored closely for rate-related adverse reactions such as headaches, chills, or blood pressure changes. It is strictly contraindicated in individuals with a history of anaphylactic reactions to human immunoglobulins or those with selective IgA deficiency.

Disclaimer: This product is a critical care prescription medication. The information provided here is for educational purposes and should not replace professional clinical guidance.